drugset / Trial / NCT04076579
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
Phase 2
Completed
29 enrolled
University of Michigan Rogel Cancer Center
AstraZeneca · collabJanssen Scientific Affairs, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well trabectedin and olaparib work in treating patients with sarcoma that cannot be removed by surgery or has spread to other places in the body. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing cells, stopping them from dividing or stopping them from spreading. Olaparib may stop the growth of tumor cells by blocking pathways responsible for repairing damaged cells. Giving trabectedin and olaparib may shrink or stop the tumor from growing.
Timeline
- Start
- 2020-03-17
- Primary completion
- 2023-01-30
- Completion
- 2024-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | — | Oral |
| Subject | Trabectedin | Small molecule | — | Intravenous |